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Abstract
Acute respiratory distress syndrome (ARDS) is a common and
often fatal inflammatory lung condition without effective
targeted therapies. Regulatory T cells (Tregs) resolve lung
inflammation, but mechanisms that enhance Tregs to
promote resolution of established damage remain unknown.
DNA demethylation at the forkhead box protein 3 (Foxp3)
locus and other key Treg loci typify the Treg lineage. To test
how dynamic DNA demethylation affects lung injury
resolution, we administered the DNA methyltransferase
inhibitor 5-aza-29-deoxycytidine (DAC) to wild-type (WT) mice
beginning 24 hours after intratracheal LPS-induced lung injury.
Mice that received DAC exhibited accelerated resolution of
their injury. Lung CD41CD25hiFoxp31Tregs fromDAC-treated
WT mice increased in number and displayed enhanced Foxp3
expression, activation state, suppressive phenotype, and
proliferative capacity. Lymphocyte-deficient recombinase
activating gene-1–null mice and Treg-depleted (diphtheria
toxin-treated Foxp3DTR) mice did not resolve their injury in
response to DAC. Adoptive transfer of 23 105 DAC-treated, but
not vehicle-treated, exogenous Tregs rescued Treg-deficient
mice from ongoing lung inflammation. In addition, in WT mice
with influenza-induced lung inflammation, DAC rescue
treatment facilitated recovery of their injury and promoted an
increase in lung Treg number. Thus, DNA methyltransferase
inhibition, at least in part, augments Treg number and function
to accelerate repair of experimental lung injury. Epigenetic
pathways represent novel manipulable targets for the treatment
of ARDS.
Keywords: DNA methylation; epigenetics; Foxp3; 5-aza-29-
deoxycytidine; acute lung injury
Clinical Relevance
No targeted therapies promote resolution of acute lung
inflammation as occurs in the acute respiratory distress
syndrome. We determined that the DNA methyltransferase
inhibitor 5-aza-29-deoxycytidine accelerated resolution of
experimental lung injury at least in part via a salutary
effect on regulatory T cell phenotype and function.
Epigenetic manipulation of the regulatory T cell lineage
represents a potential therapeutic strategy for acute
respiratory distress syndrome and other acute
inflammatory disorders.
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Acute respiratory distress syndrome
(ARDS), an inflammatory condition caused
by direct or indirect lung injury, is
a common life-threatening disease (1).
Despite extensive investigation into initial
events that cause ARDS pathology, no
targeted therapies promote repair in the
damaged lung. Resolution of inflammation
after acute lung injury is an active process
(2) that required CD41CD251Foxp31
regulatory T cells (Tregs) in a direct lung
injury mouse model: intratracheal LPS
administration (3). In that model, surviving
wild-type (WT) mice spontaneously
resolved their injury 7 to 10 days after
receiving LPS. Lymphocytes did not
determine initial injury severity; however,
injury resolution required lymphocytes as
evidenced by unremitting LPS-induced
lung inflammation in lymphocyte-deficient
recombinase activating gene-1–null
(Rag-12/2) mice. Using adoptive transfer
experiments, we identified the Treg
subpopulation as the active lymphocyte
fraction involved in promoting resolution
via pro-repair effects on macrophage
inflammatory function, neutrophil
efferocytosis, epithelial proliferation (4),
and limitation of fibroproliferation (5).
Tregs also promote repair in other tissue
damage models and in clinical scenarios
(6, 7). Although Treg transfer may be
a viable management strategy for chronic
conditions (7), the briskly evolving nature
of ARDS makes cell transfer–based therapy
impractical.
Tregs comprise a CD41 lymphocyte
subset that attenuates both innate and
adaptive immune responses (8). Treg
development and function require
epigenetic programming—prominently
through DNA demethylation—and
forkhead box protein 3 (Foxp3)
transcription factor expression (9, 10).
Constitutive Foxp3 expression is necessary
for Treg suppressive activity (11, 12), and
epigenetic marks regulate transcription at
the Foxp3 locus and the loci of other key
Treg genes (9, 13). In mice and humans,
distinct regions within Treg gene loci
(including Foxp3) display cytosine-
phospho-guanine (CpG) methylation
patterns that differ between Tregs and
CD41CD252 conventional T cells, with
hypomethylation dominating in Tregs (9,
14–18). Foxp3 expression correlates with
Treg suppressive function (10, 19, 20).
Epigenetic mechanisms may therefore
represent potential targets to rapidly
expand Treg numbers and enhance their
function (21).
DNA methyltransferases (DNMTs)
control de novo and maintenance CpG
methylation during cell division and
development (22). CpG methylation within
promoters and transcription factor binding
sites represses gene transcription, and
DNMT inhibition or knockdown can lead
to DNA demethylation. DNMTs determine
Foxp3 expression and Treg identity
because DNMT silencing or inhibition via
siRNA or 5-aza-29-deoxycytidine (DAC),
respectively, lead to Foxp3 expression and
Treg phenotype in naive CD41 non-Treg
cells (16, 23–25).
Because of the vital importance DNA
demethylation has in Treg biology, we
hypothesized that pharmacologic DNMT
inhibition would lead to enhanced repair
after lung injury via a beneficial effect
on Tregs. Our results demonstrate that
Treg DNMT inhibition augmented Treg
suppressive phenotype and function and
accelerated resolution of direct lung injury.
Some of the results of these studies have




C57BL/6 WT and Rag-12/2 mice were
purchased from Jackson Laboratory (Bar
Harbor, ME). Foxp3DTR mice were a gift
from Alexander Rudensky (Sloan-Kettering
Institute, New York, NY). Animals were
bred and housed in a pathogen-free facility.
All animal protocols were approved by the
Johns Hopkins Animal Care and Use
Committee. Male mice aged 8 to 10 weeks
were used.
Preparation of Mice
After anesthesia and tracheal intubation,
Escherichia coli O55:B5 LPS (4 mg/kg)
(Sigma-Aldrich, St. Louis, MO) or sterile
water was injected into the trachea (3).
Beginning 24 hours later, DAC (1 mg/kg)
(Sigma-Aldrich) or vehicle was
administered via daily intraperitoneal
injection. Diphtheria toxin (List Biologicals,
Campbell, CA) was administered
intraperitoneally as described in the online
supplement. For influenza experiments, 600
EID50 units of A/PR/8/34 H1N1 influenza
virus (Charles River Laboratories,
Wilmington, MA) was administered
intratracheally. Vehicle or DAC was given
as above on Days 3 through 7 after inoculation.
After mice were killed, bronchoalveolar
lavage (BAL) fluid analysis and lung
histology were performed as previously
described (3).
Flow Cytometry
Right lungs were enzymatically digested,
and a single cell suspension was created.
Cells were prepared for FACS analysis
(3) with a live-dead discriminator and
fluorochrome-conjugated antibodies
described in the online supplement. Our
Treg gating strategy is shown in Figure
E1 in the online supplement. Mean
fluorescence intensity was calculated as the
geometric mean of the positive population
fluorescence.
Lymphocyte Culture
Splenic CD41CD251 cells (. 85%
Foxp31) and CD41CD252 cells were
isolated using magnetic bead separation
(Miltenyi Biotec, Auburn, CA). Cells were
then plated in media (28) with plate-
bound anti-CD3, soluble anti-CD28
(eBioscience, San Diego, CA), and
recombinant murine IL-2 (Peprotech,
Rocky Hill, NJ). Cells were incubated for
48 hours with vehicle or 10 or 100 nM
DAC before downstream application.
DNA Methylation
After DNA isolation with an AllPrep DNA/
RNA Micro kit (Qiagen, Valencia, CA),
global DNA methylation was measured on
100 ng of DNA using an Imprint Methylated
DNA Quantification kit (Sigma-Aldrich)
and compared with a methylated DNA
control.
Lymphocyte Suppression Assay
Tregs cultured as above were incubated with
anti-CD3/CD28–coated latex microbeads
and CellTrace Violet-pulsed (Invitrogen,
Carlsbad, CA) CD41CD252 effector T cells
purified by magnetic bead separation (28).
After 72 hours, effector T cell proliferation
was assayed by flow cytometry.
Adoptive Transfer
After 48 hours in culture with vehicle or
100 nM DAC as above, 2 3 105 live Tregs
were administered via retro-orbital
injection to Treg-depleted Foxp3DTR mice
1 hour after intratracheal LPS.
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Statistical Analysis
Groups of five to nine mice were used for all
experiments (29). In vitro experiments
were performed in triplicate and repeated
at least three times. Values are reported as
mean 6 SEM. Differences between groups
were compared using two-tailed Mann-
Whitney U tests or Student’s t tests with
Holm-Sidak correction for multiple
comparisons (mean fluorescence intensity
data). Multiple group comparisons were
performed using one-way ANOVA or
one-way ANOVA on ranks. Mortality
differences were analyzed with the Mantel-
Cox test. Significance was determined at
a values ,0.05.
Results
DAC Augments Lung Treg Number
We first determined if the DNMT inhibitor
DAC could expand lung Treg number under
noninjurious circumstances. As a sham
condition for lung injury, WT mice
received an intratracheal sterile water dose
on Day 0. They then received daily
intraperitoneal DAC or vehicle on Days 1
through 4. On Day 5 after water, DAC-
treated mice displayed a higher lung Treg
number than vehicle-treated mice (Figure
E2A). Lung Treg Foxp3 expression
increased modestly in the treatment group
(Figure E2B).
To ensure that the drug itself did not
contribute to lung injury, we performed
BAL for total protein concentration—a lung
permeability marker—as well as histologic
examination. BAL protein was low overall
and did not change with DAC treatment
compared with vehicle control after
intratracheal water (Figure E2C). Lung
histology (Figure E2D) was normal after
4 days of DAC or vehicle treatment.
Neither group lost weight or experienced
mortality (data not shown). Collectively,
DAC increased lung Treg number and
Foxp3 expression in a dose that did not
cause pulmonary or overt systemic toxicity.
DAC Accelerates Resolution of
Lung Injury
Because Tregs resolve acute lung
inflammation and DAC expanded lung
Treg number and frequency in our initial
experiments, we examined if DAC could
enhance resolution of severe intratracheal
LPS-induced lung injury. WT mice received
DAC or vehicle starting 24 hours after injury
with intratracheal LPS. Mice in the vehicle
group had sustained weight loss, whereas
DAC-treated mice steadily regained weight
after initial injury (Figure 1A). Mortality
was 28.5% in the vehicle group and 0% in
the DAC group (P = 0.029, Mantel-Cox
test). Vehicle- and DAC-treated mice had
similar early injury as measured by BAL
protein, cell count, neutrophil count, and
lung histology 2 days after injury (Figures
1B–1E). At Day 5 after LPS, DAC-treated
mice, but not vehicle-treated mice,
displayed a resolving phenotype with
resolving injury parameters (Figures
1B–1E). In summary, DAC did not affect
early injury but accelerated resolution in
WT mice.
DAC Augments Lung Treg Number
and Suppressive Phenotype after
LPS Injury
Because Tregs resolve lung injury after LPS
injury (3), we characterized the Treg
response to systemic DNMT inhibition
after injury. Lung Treg number and
frequency increased significantly at Day 5
after injury in response to DAC treatment
(Figure 2A); at 2 days after injury (after one
DAC dose), there was no effect on lung
























































































































Figure 1. 5-aza-29-deoxycytidine (DAC) treatment promotes resolution of lung injury in wild-type
(WT) mice. (A) Body weight relative to baseline was plotted after injury. (B–D) Bronchoalveolar lavage
(BAL) total protein (B), total cell counts (C), and neutrophil counts (D) were determined in WT mice
2 and 5 days after injury with intratracheal (i.t.) LPS. (E) Lung sections 2 and 5 days after injury were
stained with hematoxylin and eosin. Original magnification: 320; 3200 (insets). *P , 0.05; †P , 0.001
(Mann-Whitney U test; n = 8 per group). Values reported are mean 6 SEM. N.S., not significant.
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(data not shown). Foxp3 expression, the
master regulator of Treg function, increased
27% in lung Tregs from DAC-treated mice
5 days after LPS injury (Figure 2B). Figure 2C
shows the Treg phenotypic response to
DAC 5 days after LPS injury. CD44, a Treg
activation marker (30), increased (Figure 2C,
top panel), as did CD39, an ecto-enzyme
that catalyzes ATP hydrolysis and serves as
an important Treg suppressive mediator
(Figure 2C, middle panel) (31). CTLA-4,
a negative signal to other immune cells (32),
was only slightly increased (Figure 2C,
bottom panel). Consistent with the overall
increase in Treg number, the percentage of
proliferating (Ki-671) Tregs increased in
DAC-treated mice (Figure 2D). DAC
treatment did not affect lung CD41Foxp32
cell frequency or phenotype (Figure E3).
Splenic Treg frequency paralleled the lung
findings (Figure E4). Thus, lung Tregs from
DNMT inhibitor–treated mice had an
augmentation of their number, activation
state, suppressive phenotype, and
proliferative capacity.
The Pro-resolution Effect of DAC
Requires Lymphocytes
DNMT inhibition has profound effects on
lymphocyte phenotype and function (13)
but can affect virtually any cell type. We
administered DAC or vehicle on Days 1
through 4 to LPS-injured, lymphocyte-
deficient (Rag-12/2) mice to test the
hypothesis that lymphocytes are involved in
the proresolution effect of DNMT inhibition
observed in WT mice. Five days after injury,
a time point when DAC-treated WT mice
exhibited a resolving phenotype, Rag-12/2
mice displayed persistent injury and could
not be rescued by DAC. They experienced
sustained weight loss, elevated BAL protein,
cell count, neutrophil count, and severe
histologic lung inflammation 5 days after
injury (Figure 3). Mortality was 50% in the
vehicle group and 44% in the DAC group
(P = 0.7, Mantel-Cox test). The nonresolving
phenotype in Rag-12/2 mice demonstrated
that lymphocytes are required for DAC to
exert its proresolution action.
Tregs Are Required for DAC-
Enhanced Resolution
We hypothesized that Tregs would be
required for DAC to exert its pro-resolution
influence. To deplete Tregs, Foxp3DTR mice
received diphtheria toxin beginning 2 days
before LPS injury and then every other day
thereafter. Similar to Rag-12/2 and in
contrast to WT mice, DAC treatment in
Treg-depleted Foxp3DTR mice did not
accelerate lung injury resolution as measured
by weight, BAL protein, cell count,
neutrophil count, and lung histology 5 days
after LPS (Figure 4). Mortality was 33%
in both groups. We confirmed lung Treg
depletion in diphtheria toxin–treated
Foxp3DTR mice compared with diphtheria
toxin–treated, LPS-injured WT mice 5 days
after injury (Figure E5A). In a pattern similar
to WT mice from Figure 1, WT mice treated
with diphtheria toxin experienced accelerated
lung injury resolution in response to DAC
(Figures E5B–E5E). These data confirmed
that DAC-enhanced resolution of lung
inflammation requires Tregs.
DAC Augments Foxp3 Expression and
In Vitro Suppressive Activity
To determine the effects of DNMT








































































































































































































Figure 2. Lung regulatory T cell (Treg) number, activation state, suppressive phenotype, and
proliferative capacity increase with DAC treatment after injury. (A) Lung CD41CD25hiFoxp31 cells
are shown as number in the right lung, frequency of lung cells, and frequency of CD41 cells 2 and
5 days after injury in WT mice. (B–D) Foxp3 (B); CD44, CD39, and CTLA-4 (C) expression; and the
percentage of Ki-671 Tregs (D) were determined by fluorescence in lung Tregs 5 days after injury.
Accompanying bar graphs show summary mean fluorescence intensity (MFI) (B and C) and the
percentage of Ki-671 Tregs (D). *P , 0.05, **P , 0.01, and †P , 0.001 (Mann-Whitney U test for cell
numbers/frequencies [A and D] or t test with Holm-Sidak correction for multiple comparisons [mean
fluorescence intensities, B and C]; n = 8 per group). Values reported are mean 6 SEM.
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CD41CD252 cells (conventional T cells)
or CD41CD251 cells (Tregs, .85%
Foxp31) with anti-CD3/CD28 antibodies
and IL-2 with or without DAC.
DAC induced Foxp3 expression in
conventional T cells and augmented
Foxp3 expression in Tregs (Figure 5A).
When cultured with DAC, Tregs
displayed increased CD44 expression
(Figure 5B, top panel). In contrast to the
in vivo findings, DAC did not augment
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Figure 3. Lymphocyte-deficient (Rag-12/2) mice do not resolve lung injury in response to DAC treatment. (A) Body weight relative to baseline was plotted after injury.
(B–D) BAL total protein (B), total cell counts (C), and neutrophil counts (D) were determined in Rag-12/2 mice 5 days after injury with LPS. (E) Lung sections were
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Figure 4. DAC does not promote resolution in Treg-depleted mice. (A) Body weight relative to baseline was plotted beginning with the first diphtheria toxin
dose (2 d before injury). Arrowheads represent diphtheria toxin (DTx) doses. (B–D) BAL total protein (B), total cell counts (C), and neutrophil counts (D) were
determined in DTx-treated Foxp3DTR mice (Foxp3DTR DTx1) 5 days after injury with LPS. (E) Lung sections were stained with hematoxylin and eosin.
Original magnification: 320; 3200 (insets). P . 0.05 (Mann-Whitney U test; n = 7 per group). Values reported are mean 6 SEM.
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Figure 5. DAC alters CD41 T cell phenotype and function in vitro. (A) Splenic WT CD41CD252 conventional T cells (Tconv) or Tregs were cultured
with DAC for 48 hours. Foxp3 fluorescence is plotted for shown DAC concentrations (vehicle, 10 and 100 nM). (B and C) CD41CD25hiFoxp31 Treg
expression of CD44, CD39, and CTLA-4 (B) and the percentage of Ki-671 Tregs (C) were determined by fluorescence in cultured Tregs treated with
vehicle or 100 nM DAC. Accompanying bar graphs show summary MFIs (A and B) and the percentage of Ki-671 Tregs (C). (D) T effector cells (Teff)
were sorted from WT spleens, labeled with CellTrace Violet, and cultured in the presence of anti-CD3/CD28 and varying Treg ratios. Tregs were previously
cultured in the presence of vehicle or 100 nM DAC. (E) Global DNA methylation was measured in Tregs cultured with vehicle or 100 nM DAC and
compared with methylated control DNA. Experiments were conducted in triplicate and repeated three times. Proliferation data are representative of three
independent experiments. *P , 0.05, **P , 0.01, and †P , 0.001 (t test with Holm-Sidak correction for multiple comparisons [MFI, A and B] or Mann-
Whitney U test [C–E]). Values reported are mean 6 SEM.
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DAC slightly increased CTLA-4
expression (Figure 5B, bottom panel).
A higher percentage of the DAC-treated
Tregs expressed Ki-67 compared with
vehicle treatment (Figure 5C). After
48 hours in culture, we tested classical
Treg suppressive activity in a mixed
lymphocyte reaction. DAC-treated Tregs
suppressed effector T cell proliferation
with greater potency than vehicle-treated
Tregs (Figure 5D). Effector T cells did
not receive DAC or vehicle treatment.
After 48 hours of culture with DAC, global
DNA methylation decreased compared
with vehicle treatment (Figure 5E).
Collectively, DNMT inhibition in culture
hypomethylated Tregs and recapitulated
some features observed in injured mice
(increased Foxp3 expression, activation,
and proliferation) but not increased
CD39 expression. DNMT inhibitor–
treated Tregs exhibited greater suppressive
function in a mixed lymphocyte
reaction.
Adoptive Transfer of DAC-Treated
Tregs Mediates Resolution
Systemic DAC administration likely affects
a myriad of cell types, so we sought to
determine how ex vivo DAC-treated
Tregs specifically influence lung injury
resolution. Our previous work suggested
that therapeutic adoptive transfer of less
than 1 3 106 vehicle-treated Tregs
would be an insufficient dose to effect
robust resolution (3). Thus, LPS-injured,
Treg-depleted Foxp3DTR mice received
2 3 105 WT splenic DAC- or vehicle-
treated Tregs via retro-orbital injection
1 hour after intratracheal LPS. Initial
injury was similar between the two
groups. Seven days after injury, mice
that received vehicle-treated Tregs
displayed unremitting lung inflammation
characterized by sustained weight loss
and elevations in BAL cell count,
neutrophil count, and protein as well
as injured histology. In contrast, lung
injury resolution occurred in mice that
received DAC-treated Tregs (Figures
6A–6E) with an increase in BAL fluid
transforming growth factor (TGF)-b
concentration among DAC-treated Treg
recipients (Figure 6F). Mortality was
25% in vehicle-treated Treg recipients
and 14% in DAC-treated Treg recipients
(P = 0.6, Mantel-Cox test). Flow cytometry
confirmed successful adoptive transfer
and homing to the lung (see Figure E1
for gating). Exogenous lung Tregs
(Foxp3-APC1GFP2) increased in mice
that received DAC-treated Tregs
compared with vehicle-treated Treg
recipients (Figure 6G). Among exogenous
Tregs, the DAC-treated phenotype
resembled the profile observed with
systemic DAC administration, with
increases in Foxp3, CD44, CD39, and
CTLA-4 expression and increases in the
percentage of Ki-671 Tregs (Figures 6H
and 6I). In summary, an otherwise
subtherapeutic Treg dose—when treated
ex vivo with DAC—facilitated lung
injury resolution.
DAC Is Beneficial in an Influenza
Model
In addition to LPS-induced lung
inflammation, we inoculated WT mice
intratracheally with a laboratory strain of
H1N1 influenza and administered DAC
or vehicle on Days 3 through 7 after
inoculation. At Day 10 after inoculation,
DAC-treated mice had a smaller magnitude
of weight loss and decreased BAL protein,
cell count, neutrophil count, and histologic
injury compared with vehicle-treated mice
(Figures 7A–7E). DAC-treated animals
displayed an increase in lung Treg number
and Foxp3 expression (Figures 7F and 7G).
Thus, rescue treatment with DAC had
favorable effects on lung injury and Tregs
in an infectious model of direct lung
inflammation.
Discussion
In this report, we establish Foxp31
regulatory T cell DNMT inhibition as an
epigenetic mechanism that accelerates
resolution of acute lung injury. The salutary
effect of DNMT inhibition required Tregs,
and our adoptive transfer experiments
confirmed that Tregs, at least in part,
mediated the inhibitor’s pro-resolution
action. Although systemic DNMT
inhibition likely acts on multiple cell types
involved in lung injury repair, Tregs
exquisitely depend on DNA demethylation
and therefore may be predisposed to the
effects of a DNMT inhibitor.
ARDS persists as a devastating disease
without targeted therapy despite extensive
insight into the initial inflammatory injury.
Therefore, we focused on events determining
resolution of lung inflammation. Resolution
of injury requires not only cessation of
ongoing pathology but also active repair of
damaged tissues (2). In contrast to reports
using pretreatment with a histone
deacetylase inhibitor (33–35), we show that
resolution can be accelerated by a DNMT
inhibitor administered after lung injury
establishment. DNMT inhibition did not
modify early LPS injury in our study,
highlighting the conclusion that dynamic
changes in DNA methylation patterns likely
occur during resolution.
We believe our findings and model
have translational relevance to ARDS.
Although systemic administration of
a DNMT inhibitor represents a potential
therapeutic strategy, ex vivo treatment of
Tregs with a DNMT inhibitor followed by
cell transfer could improve the drug’s
therapeutic index. Adoptive transfer of Tregs
that have been expanded or modified
ex vivo is a validated experimental therapy to
promote resolution of acute and chronic
inflammatory conditions (7). Diseases with
a predictable time course, such as graft-
versus-host disease, represent ideal disorders
for Treg-based clinical immunotherapy
(36–38). However, the timescale required
to generate a therapeutic Treg dose is on
the order of weeks (39, 40)—too long for
a practical ARDS treatment. Epigenetic
modification using DNMT inhibition to
rapidly augment Treg number and
function either in vivo or ex vivo holds
translational potential for acute
inflammatory diseases, including ARDS.
Our model—sterile direct lung injury
using the gram-negative bacterial cell
wall component LPS—is a well-
characterized system to study lung
inflammation (41) and recapitulates many
ARDS features, including neutrophilic
alveolitis, modest mortality, and
spontaneous resolution in survivors (3).
Our sterile inflammatory model has
relevance for many ARDS causes, including
aspiration of gastric contents, ventilator-
induced lung injury, near drowning, and
collateral lung injury associated with
treated bacterial infection. Moreover, our
data using an influenza model broaden the
applicability of epigenetic manipulation as
a therapeutic strategy for ARDS.
We chose to use diphtheria
toxin–treated WT mice as controls for our
experiments using Foxp3DTR mice, which
express a normal Foxp3 protein and
a diphtheria toxin receptor–green
fluorescent protein fusion product.
Although mice expressing a Foxp3-green
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Figure 6. Adoptive transfer (AT) of DAC-treated Tregs rescues the injury phenotype in Treg-depleted mice (Foxp3DTR DTx1). (A) Body weight relative to
baseline was plotted after injury. Arrowheads represent DTx doses. (B–D) BAL total protein (B), total cell counts (C), and neutrophil counts (D)
were determined in Treg-depleted mice 7 days after injury with LPS. (E) Lung sections 7 days after injury were stained with hematoxylin and eosin.
Original magnification: 320; 3200 (insets). (F) Transforming growth factor (TGF)-b concentrations were measured in BAL fluid. (G) Exogenous
(CD41CD25hiAPC1GFP2) lung Tregs are shown as number in the right lung, frequency of lung cells, and frequency of CD41 cells 7 days after injury.
(H and I) Foxp3 (H); CD44, CD39, and CTLA-4 expression; and the percentage of Ki-671 Tregs (I) were determined by fluorescence in exogenous lung
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fluorescent protein fusion protein
(Foxp3gfp) have facilitated studies of Treg
biology (42), these mice exhibit abnormal
Treg epigenetic programming due to the
altered Foxp3 protein (43). Thus, we
selected mice with a normal Foxp3
protein to ensure fidelity of epigenetic
responses.
Despite their rarity, Tregs coordinate
resolution of direct lung injury via cellular
interactions that lead to pro-repair effects
on alveolar macrophage responses (3),
epithelial regeneration (4), and limitation of
fibrocyte-mediated fibrosis (5). However,
the specific Treg subset involved in injury
resolution remains undefined. Ex vivo
treatment of Tregs with DAC followed by
adoptive transfer to LPS-injured, Treg-
depleted animals increased BAL fluid
TGF-b concentration compared with ex vivo
vehicle treatment. Tregs require TGF-b to
effect repair after LPS injury (3), which
indicates that peripherally induced Tregs
(pTregs or iTregs) may be the responsible
fraction. However, thymus-derived natural
Treg (tTreg or nTreg) expansion or
recruitment could also contribute to the
lymphocyte response after lung injury
because adoptive transfer of 13 106 splenic
nTregs mediates resolution in lymphocyte-
deficient mice (3, 5). The CpG methylation
signature of Treg gene loci distinguishes
committed thymus-derived Tregs and
TGF-b–induced Tregs (9). Our study is
limited in that we did not directly measure
region-specific CpG methylation patterns;
however, others have described that Treg
induction in the presence of a DNMT
inhibitor generates a thymus-derived Treg
epigenetic profile (9, 21, 25). Although
outside the scope of this report, our group
is pursuing lung Treg CpG methylation
pattern analysis paired with gene
expression profiling to determine the
significance of Treg epigenetic signatures
after injury and with DNMT inhibitor
treatment.
Our flow cytometric molecular
phenotyping data suggest several
mechanisms involved in DAC-enhanced
injury repair. DNMT inhibition modestly
augmented Foxp3 expression (18, 24),
which leads to increased Treg proliferation
and immunoregulatory activity (10, 19, 20).
Our in vitro experiments showed that DAC
induces Foxp3 expression in non-Tregs.
These results lend speculation to the idea
that conversion of naive CD41 T cells into
Foxp31 cells (24) partially underlies the
Treg increase observed in DAC-treated
mice. However, the functional abilities of
these converted cells remain unclear, at
least in in vitro systems (44), and our
data showed a large difference in Foxp3
expression between DAC-induced Foxp31
cells and Foxp31 Tregs cultured with DAC.
A recent report demonstrated that deletion
of the DNMT adapter protein Uhrf1 within
CD41 cells reduced production of Tregs
due to hypomethylation at the locus
encoding the cyclin-dependent kinase
inhibitor p21 (45). In contrast, our data
suggest that demethylation in committed
CD41CD25hiFoxp31 cells is different than
demethylation in undifferentiated CD41
cells because demethylation in Foxp31 cells
led to proliferation of committed Tregs
in vitro, with in vivo data showing nominal
effects on CD41Foxp32 cells. In addition,
a study using mice with Dnmt1 deletion
restricted to Foxp31 cells suggested that
Tregs require the Dnmt1 isoform to execute
their suppressive program (46). Based
on our data, we hypothesize that
pharmacologic demethylation on an acute
timescale leads to different methylation
patterns than those accompanying genetic
deletion of Dnmt1. We acknowledge that
our present study is limited to address this
hypothesis in a direct fashion.
Phenotypically, Treg CD39 surface
expression increased in response to DAC
after lung injury, suggesting extracellular
ATP hydrolysis as a mechanism by which
Tregs exert their pro-repair program after
DNMT inhibition. Damaged cells release
ATP into the extracellular milieu, where it
exhibits multiple proinflammatory effects;
CD391 Treg-mediated ATP hydrolysis
can restore homeostasis to injured tissues
(31). DAC did not increase Treg CD39
expression in the absence of inflammation
in vitro (Figure 5) or after intratracheal
water (data not shown). However, lung
Treg CD39 expression increased after
adoptive transfer of DAC-treated Tregs to
an injured host. These data indicate that
environmental conditions in the inflamed
lung may combine with the Treg
epigenetic state to modulate gene and
protein expression profiles. CTLA-4 was
only slightly up-regulated with systemic
DAC treatment and, although statistically
different, does not likely have biological
relevance (32). Treg proliferation
increased in response to DAC. Indeed,
lung Treg number increased significantly
in DAC-treated mice compared with
vehicle 5 days after LPS injury, and DAC
treatment led to robust proliferation after
adoptive transfer. Finally, although not
directly addressed by our experimental
design, more efficient Treg homing to the
inflamed lung could also contribute to
accelerated repair. Although DAC
modestly increases individual Treg
markers, the combined effect on Treg
function could be synergistic. Collectively,
both a qualitative mechanism
(augmentation of Treg suppressive
function) and a quantitative mechanism
(increased Treg proliferation) may
underlie the pro-resolution effect of
DNMT inhibition.
The present study raises several
questions. (1) What other cell types
undergo epigenetic changes in response to
lung injury? A recent investigation showed
that dual therapy with histone acetylation
and DNA methylation modifiers can
mitigate lung vascular hyperpermeability
after systemic LPS injury in mice—
an indirect lung injury model—via
a beneficial effect on the pulmonary
endothelium (47). Dynamic DNA
methylation in non-Treg cells after lung
injury remains to be explored. (2)
What DNA methylation pattern do
Tregs that respond to lung injury display?
We determined that inhibition of
Treg DNA methylation after injury
promotes resolution, but it is unclear if
induced or thymus-derived Tregs drive
lung injury repair. Future experiments
with lung Treg CpG methylation pattern
analysis will help determine the subset
involved in the Treg response to injury.
(3) What effect does Treg plasticity have
on the lung injury phenotype?
Figure 6. (Continued). Tregs 7 days after injury. Accompanying bar graphs show summary MFIs (H and I) and the percentage of Ki-671 Tregs (I, last panel).
*P, 0.05 and †P , 0.001 by Mann-Whitney U test (lung injury parameters, TGF-b levels, and cell numbers/frequencies, A–D, F, G, and I [last panel] or t test
with Holm-Sidak correction for multiple comparisons (MFI, H and I [first three panels]) (n = 6 per group). Values reported are mean 6 SEM.
ORIGINAL RESEARCH
Singer, Mock, Aggarwal, et al.: DNA Methyltransferase Inhibition Resolves Injury 649
 
Controversy surrounds whether
committed Tregs undergo Foxp3
down-regulation or loss and assume
T effector function in inflammatory
environments (48, 49). Because DNA
demethylation stabilizes Tregs, it is
possible that pharmacologic DNMT
inhibition after injury helps to maintain
and stabilize Treg identity and mitigate
any effect of Foxp3 loss that might
otherwise occur (50). Fate-mapping






































































































































































































































Figure 7. DAC rescue treatment has favorable effects in an influenza (flu) model. (A) Body weight relative to baseline is shown 10 days after inoculation
with influenza. (B–D) BAL total protein (B), total cell counts (C), and neutrophil counts (D) were determined in WT mice 10 days after intratracheal
inoculation with influenza. (E) Lung sections 10 days after inoculation were stained with hematoxylin and eosin. Original magnification: 320; 3200 (insets).
(F) Lung CD41CD25hiFoxp31 cells are shown as number in the right lung, frequency of lung cells, and frequency of CD41 cells 10 days after inoculation.
(G) Foxp3 expression was determined by fluorescence in lung Tregs. The accompanying bar graph shows summary mean fluorescence intensities.
*P , 0.05, **P , 0.01, and †P , 0.001 (Mann-Whitney U test; n = 9 per group). Values reported are mean 6 SEM.
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Treg plasticity affects lung injury
pathology and resolution.
In conclusion, we report a role
for regulatory T cell DNMT inhibition
in resolution of acute lung injury.
DNMT inhibition increases lung
Treg frequency and suppressive
phenotype and function to promote
resolution. Further investigation into the
epigenetic marks and mechanisms
underlying our findings may lead to
therapeutic options for patients with
ARDS and other acute inflammatory
conditions. n
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